Description
Product Name: Ipamorelin
Batch Number: CT-A-IP
CAS Number: 170851-70-4
Ipamorelin is a high-purity synthetic peptide frequently utilized in experimental systems as a selective growth hormone secretagogue receptor (GHS-R) agonist. It is used as a research tool in preclinical and in-vitro models to investigate peptide-mediated signaling, endocrine regulation, and growth hormone–related pathways.
ChemTide supplies Ipamorelin exclusively for laboratory research performed by qualified professionals. This material is not a finished drug product and is not approved for any form of clinical, therapeutic, or diagnostic application.
Key Features
-
Compound: Ipamorelin
-
CAS: 170851-70-4
-
Type: Synthetic research peptide
-
Reported activity: Selective GHS-R agonist in experimental systems
-
Intended use: In-vitro and other controlled laboratory research applications
-
Batch: CT-A-IP
Intended Use
This product is supplied solely for:
-
Laboratory-based research
-
In-vitro assays
-
Method development and mechanistic studies
It is not intended for:
-
Human consumption or administration
-
Veterinary use
-
Medical, diagnostic, or therapeutic applications
-
Cosmetic or food use
Handling & Safety
-
Handle only in appropriately equipped research facilities.
-
Use suitable personal protective equipment (PPE) and follow institutional safety protocols.
-
Consult your organization’s safety officer or relevant guidelines before use.
-
Refer to your in-house SDS and institutional procedures for detailed handling and disposal information.
Legal & Compliance Notice
By purchasing Ipamorelin (Batch CT-A-IP), the buyer confirms that they are a qualified professional or institution, that the product will be used only for lawful research purposes, and that they understand and accept ChemTide’s Research Use Only, Terms of Use, and Return & Refund Policy.
All products sold by ChemTide, LLC are intended for laboratory research use only.
Not for human or veterinary consumption, medical use, or diagnostic purposes.
Reviews
There are no reviews yet.